| Revenue growth | Flat YoY at ₹1,051cr; 9-month revenue up 3%. |
|---|---|
| Margins | EBITDA margin stable at 13%; Specialty segment sustained >25%. |
| Order book | Funnel expanded to 100+ opportunities with ₹3,500cr peak revenue potential. |
| Demand visibility | Strong recovery in agrochemical volumes; stable pharmaceutical demand. |
| Management confidence | Confident, focusing on new project execution and volume resilience. |
Growth
Revenue grew 3% for nine months with double-digit volume growth; EBITDA rose 8%.
Outlook
Projecting ₹500cr capex in FY27; CDMO order deliveries starting March 2026.
Risks
Subdued pricing in Specialty Chemicals and Vitamin B3; supply-demand imbalances in agrochemicals.
Earnings Call filed with NSE, NSE: JUBLINGREA. Summary written with AI assistance from the document.
Jubilant Ingrevia Ltd: key numbers
- Share price
- ₹656.10
- Market cap
- ₹10,450 Cr
- Revenue (annual)
- ₹4,388 Cr
- Net profit (annual)
- ₹277.9 Cr
- P/E (TTM)
- 33.9×Sector 37.5×
- Promoter holding
- 45.22%+0.00% QoQ
- FII holding
- 6.49%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Ingrevia Ltd
All →Jubilant Ingrevia Debt & Borrowing: ₹100 Cr
Jubilant Ingrevia has issued Commercial Papers worth Rs. 100 Crore. This issuance, with a 90-day tenure, falls within the previously approved Rs. 600 Crore outstanding limit.
- Value
- ₹100.0 Cr
Jubilant Ingrevia Employee Stock Options
Jubilant Ingrevia Employees Welfare Trust sold 8,807 shares worth Rs.0.56 Crore. The sale was executed to facilitate the exercise of ESOP options.
- Value
- ₹0.56 Cr
Jubilant Ingrevia Capital Structure Change
Jubilant Ingrevia Employees Welfare Trust sold 2,587 equity shares worth Rs. 0.17 Crore on September 11, 2026.
- Value
- ₹0.17 Cr
Jubilant Ingrevia Employee Stock Options
Jubilant Ingrevia Employees Welfare Trust sold 5,622 equity shares for Rs. 0.38 Crore. The transfer was executed pursuant to the exercise of ESOPs.
- Value
- ₹0.38 Cr
Jubilant Ingrevia Investor Presentation: Key Takeaways
Jubilant Ingrevia reported a strong Q1 FY27 with revenue at a 15-quarter high of INR 1,300 Cr (up 25% YoY). Strategy focuses on the 'Pinnacle' journey, expanding CDMO and Specialty Chemical pipelines.
Jubilant Ingrevia Q1 FY27 Results: Net Profit ₹106 Cr, Up 41.3% YoY
Jubilant Ingrevia Ltd reported revenue from operations of ₹1,300 Cr (+25.2% YoY) and net profit of ₹106 Cr (+41.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹106 Cr · +41.3% YoY